Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E W Sutherland

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Clinical Pharmacology and Therapeutics|February 1, 1980
Displacement of phenytoin from plasma binding sites by salicylateD G Fraser, T M Ludden, R P Evens, et al.
American Journal of Hospital Pharmacy|February 1, 1980
Phenytoin toxicity and blood levels after a large oral doseR P Evens, D G Fraser, T M Ludden, et al.
The Journal of Cell Biology|November 1, 1976
Adenosine 3':5'-monophosphate content and actions in the division cycle of synchronized HeLa cellsC E Zeilig, R A Johnson, E W Sutherland, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1973
The importance of calcium ions for the regulation of guanosine 3':5'-cyclic monophosphage levelsG Schultz, J G Hardman, K Schultz, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1973
A new enzymatic assay for guanosine 3':5'-cyclic monophosphate and its application to the ductus deferens of the ratG Schultz, J G Hardman, K Schultz, et al.
Endocrinology|February 1, 1973
Effects of methylxanthines on adenosine 3',5'-monophosphate and corticosterone in the rat adrenalA Peytremann, W E Nicholson, G W Liddle, et al.
Medical Toxicology and Adverse Drug Experience|March 1, 1988
Pharmaceutical excipients. Adverse effects associated with inactive ingredients in drug products (Part I)L K Golightly, S S Smolinske, M L Bennett, et al.
The Journal of Clinical Investigation|December 1, 1970
Kinetic parameters and renal clearances of plasma adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in manA E Broadus, N I Kaminsky, J G Hardman, et al.
Medical Toxicology and Adverse Drug Experience|May 1, 1988
Pharmaceutical excipients. Adverse effects associated with 'inactive' ingredients in drug products (Part II)L K Golightly, S S Smolinske, M L Bennett, et al.
The Journal of Biological Chemistry|April 25, 1971
Effects of guanosine 3',5'-monophosphate on the perfused rat liverJ H Exton, J G Hardman, T F Williams, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Clinical Pharmacology and Therapeutics|February 1, 1980
Displacement of phenytoin from plasma binding sites by salicylateD G Fraser, T M Ludden, R P Evens, et al.
American Journal of Hospital Pharmacy|February 1, 1980
Phenytoin toxicity and blood levels after a large oral doseR P Evens, D G Fraser, T M Ludden, et al.
The Journal of Cell Biology|November 1, 1976
Adenosine 3':5'-monophosphate content and actions in the division cycle of synchronized HeLa cellsC E Zeilig, R A Johnson, E W Sutherland, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1973
The importance of calcium ions for the regulation of guanosine 3':5'-cyclic monophosphage levelsG Schultz, J G Hardman, K Schultz, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1973
A new enzymatic assay for guanosine 3':5'-cyclic monophosphate and its application to the ductus deferens of the ratG Schultz, J G Hardman, K Schultz, et al.
Endocrinology|February 1, 1973
Effects of methylxanthines on adenosine 3',5'-monophosphate and corticosterone in the rat adrenalA Peytremann, W E Nicholson, G W Liddle, et al.
Medical Toxicology and Adverse Drug Experience|March 1, 1988
Pharmaceutical excipients. Adverse effects associated with inactive ingredients in drug products (Part I)L K Golightly, S S Smolinske, M L Bennett, et al.
The Journal of Clinical Investigation|December 1, 1970
Kinetic parameters and renal clearances of plasma adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in manA E Broadus, N I Kaminsky, J G Hardman, et al.
Medical Toxicology and Adverse Drug Experience|May 1, 1988
Pharmaceutical excipients. Adverse effects associated with 'inactive' ingredients in drug products (Part II)L K Golightly, S S Smolinske, M L Bennett, et al.
The Journal of Biological Chemistry|April 25, 1971
Effects of guanosine 3',5'-monophosphate on the perfused rat liverJ H Exton, J G Hardman, T F Williams, et al.
Pageof 6